ASCO 2021 | Venetoclax and R2 in mantle cell lymphoma
Tycel J. Phillips, MD, Michigan Medicine Hematology Clinic, Ann Arbor, MI, discusses results from the multi-center Phase I study (NCT03523975) of venetoclax and R2 (lenalidomide and rituximab) in patients with newly diagnosed mantle cell lymphoma (MCL). Out of 28 patients, three had p53 mutations did not respond to treatment or relapsed whereas the rest responded to treatment. Patients who received at least six months of treatment are currently in molecular remission. A further study incorporating a bispecific antibody to the aforementioned treatment regimen for patients with P53 mutations is also planned. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Tycel J. Phillips, MD has received research support from Abbvie, BMS, Bayer. Ad Board: Abbvie, ADCT, Astra Zeneca, Bayer, BMS, Incyte, Gilead, Genentech, Pharmacyclics.
